You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Reversal of Tau Pathology with MSUT2 siRNA Conjugates
SBC: DTx Pharma, Inc. Topic: NIAProject Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Sorting live cells using RNA-targeting CRISPR-Cas9 (RCas9)
SBC: DAHLIA BIOSCIENCES, INC. Topic: 172Project Summary/Abstract Transcriptomic-based approaches, and in recent years, single-cell RNA sequencing, are revolutionizing our understanding of cellular heterogeneity, opening up a new route to identify novel cell markers at unprecedented scale across many different cell types. RNA-based live-cell sorting opens up andgt;99% of the marker space to enable higher specificity cell sorting. Howe ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Recombinant Fc fusions for treatment of uropathogenic E. coli
SBC: Planet Biotechnology Incorporated Topic: 300Urinary tract infections (UTIs) are among the most common bacterial infections, affecting 150 million people worldwide each year. In the USA, community-acquired UTIs account for about 11 million cases each year that cost the U.S. public health budget $5 billion annually. Uropathogenic Escherichia coli (UPEC) accounts for up to 80% of UTIs. While UTIs are currently treated with antibiotics, the fre ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Treat Ulcerative Colitis
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: 300PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from Ulcerative Colitis (UC), which is estimated to impact approximately one million adults in the United States, leading to morbidity, heightened risk of cancer, and mortality. In multiple preclinical studies, we and others have defined the therapeutic potential of low-dose exogenous carbon m ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NHLBIPROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents
SBC: Grannus Therapeutics, Inc. Topic: NCIAbstract The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small molecule inhibitors of Hsp90 have entered clinical trials for ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Detection of perfuorooctanoic acid (PFOA) and perfluorooctane sulfonate(PFOS) in liquid samples.
SBC: SEACOAST SCIENCE, INC. Topic: NIEHSPerfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate) are toxic and persistent compounds resulting from the production and use of fluoropolymers such as Gortex® and Teflon ®. The structure of PFAS preclude environmental degradation and can lead to bioaccumulation in animals and humans. Reported adverse effects of these compounds in humans include: ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
MITOCHONDRIAL RESPIROMETRY IN FROZEN BIOLOGICAL SAMPLES
SBC: Enspire Bio, Inc. Topic: NIEHSAbstractImpaired mitochondrial respiration plays a key role in metabolic, cardiovascular, and aging-related diseases. However, mitochondrial respirometry analysis currently requires processing of the living tissue sample within an hour after being taken from the patient. This requirement makes respirometry analysis largely unfeasible to standard clinical practice and clinical studies. We invented ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel QcrB Inhibitors for the Treatment of Tuberculosis
SBC: LGENIA INC. Topic: NIAIDAbstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Q-GRFT Enema Development Supporting a Multi-Administration Clinical Study
SBC: Grow Biomedicine LLC Topic: NIAIDProject Summary Unprotected receptive anal intercourse (RAI) is the sexual behavior with the highest per-act risk of HIV acquisition, conferring 10 to 20 times more risk than unprotected vaginal intercourse. We are developing an antiviral rectal rinse (enema) using a novel HIV entry inhibitor, the lectin Griffithsin (GRFT), because there is a lack of on-demand antiviral HIV prevention products tha ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health